BIO Charges Express Scripts, PCMA With Over Estimating Follow-On Biologic Savings
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry group issues white paper outlining “seriously flawed assumptions” made in the two reports.
You may also be interested in...
Follow-On Biologics Would Save $71 Billion Over 10 Years, Express Scripts Estimates
The PBM report models savings stemming from the use of biosimilars for interferons, erythropoietin, growth hormone and insulin.
Generic Biologics Bill’s Key Battleground May Be Senate Health Committee
Reintroduced legislation drops tax credits for development of follow-ons. Sponsors see PDUFA reauthorization as ideal vehicle.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.